A fraction of NSCLC was identified to have active mutations of the epidermal growth factor receptor (EGFR) gene, and tumors with EGFR mutations were extremely responsive to EGFR-TKI [34]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.